Intravenous Immunoglobulin Pipeline Analysis Report 2026

Intravenous Immunoglobulin plays a crucial role in managing immune deficiencies and autoimmune disorders by restoring essential antibodies. Over 6 million people worldwide are estimated to live with primary immunodeficiency disorders, yet 70-90% remain undiagnosed. Globally, PIDs affect approximately 1 in 10,000 people, with regional prevalence reaching 4.4 cases per 100,000 in France, underscoring the critical role of IVIG therapy. The intravenous immunoglobulin pipeline analysis highlights expanding development activity, new formulation innovations, and broader therapeutic exploration. This trend highlights rising demand for safer, more effective, and targeted immunoglobulin-based treatment options across diverse patient populations.

Report Coverage

The Intravenous Immunoglobulin Pipeline Analysis Report gives comprehensive insights into intravenous immunoglobulin therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for intravenous immunoglobulin. The intravenous immunoglobulin report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The intravenous immunoglobulin pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with intravenous immunoglobulin treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to intravenous immunoglobulin.

Intravenous Immunoglobulin Pipeline Outlook

Intravenous immunoglobulin is a blood-derived therapy composed of pooled immunoglobulin G antibodies extracted from donor plasma. It is used to modulate immune responses in various autoimmune and immunodeficiency disorders. Keywords such as IVIG therapy, immune globulin, antibody infusion, plasma therapy, immunotherapy IV, and IVIG treatment highlight its clinical relevance and mechanism.

Intravenous immunoglobulin is treated using controlled administration of passive immunity, IgG therapy, and infusion therapy to enhance immune support and regulate abnormal immune activity in affected patients. In December 2025, the FDA approved a 10% IVIG formulation, QIVIGY, for adults with primary humoral immunodeficiency, offering enhanced dosing flexibility and improved patient convenience. This milestone highlights active development in next-generation IVIG therapies, emphasizing continuous optimization of safety, efficacy, and accessibility for patients worldwide.

Intravenous Immunoglobulin Epidemiology

Intravenous immunoglobulin (IVIG) therapy is primarily used to manage primary immunodeficiency disorders (PIDs), rare genetic conditions that compromise immune function. It is estimated that over 6 million people worldwide live with PIDs, though approximately 70-90% remain undiagnosed due to gaps in awareness and diagnostic capacity. PIDs affect approximately 1 in 10,000 people globally, with prevalence varying regionally, such as about 4.4 cases per 100,000 in France. Intravenous immunoglobulin remains a cornerstone treatment, providing essential antibody replacement and reducing infection risk in affected individuals with rare disease, supporting PID treatment, improving outcomes in CIDP, aiding in Kawasaki management, and delivering clinical benefits.

Intravenous Immunoglobulin - Pipeline Therapeutic Assessment

This section of the report covers the analysis of intravenous immunoglobulin drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The intravenous immunoglobulin pipeline analysis report covers 50+ drug analyses based on drug classes:

• Polyclonal Immunoglobulins
• Monoclonal Antibodies
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Intravenous Immunoglobulin Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total intravenous immunoglobulin clinical trials. Phase 1 (22%), Phase 2 (29%), Phase 3 (37%), and Phase 4 (12%). Overall, the distribution highlights a late-stage-heavy pipeline, reflecting the mature development pathway of intravenous immunoglobulin therapies.

Intravenous Immunoglobulin Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the intravenous immunoglobulin pipeline analysis include polyclonal immunoglobulins, monoclonal antibodies, and peptides. The intravenous immunoglobulin report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for intravenous immunoglobulin. For instance, in June 2024, Grifols’ Biotest received FDA approval for Yimmugo®, an innovative intravenous immunoglobulin (IVIG) therapy to treat primary immunodeficiencies (PID), marking the first U.S. approval of a Biotest‑developed product. Developed using a state‑of‑the‑art process at its FDA‑certified facility in Germany, Yimmugo expands Grifols’ immunoglobulin portfolio and addresses growing demand for plasma‑derived treatments in PID care.

Intravenous Immunoglobulin Clinical Trials - Key Players

The report for the intravenous immunoglobulin pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed intravenous immunoglobulin therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in intravenous immunoglobulin clinical trials:

• AbbVie
• CSL Behring
• Marengo Therapeutics, Inc.
• Kedrion S.p.A.
• CatalYm GmbH
• Takeda Pharmaceuticals
• GC Biopharma Corp
• argenx
• Endeavor Health
• ViiV Healthcare

Intravenous Immunoglobulin - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for intravenous immunoglobulin. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of intravenous immunoglobulin drug candidates.

Biological: IGI 10%

IGI 10% is a highly purified intravenous immunoglobulin (IVIG) biological therapy designed to provide passive immunity in patients with antibody deficiencies. It works by supplying concentrated IgG antibodies that help neutralize pathogens and modulate dysregulated immune responses across various immune-mediated disorders. IGI 10% is being studied by GC Biopharma, a global leader in plasma-derived therapies known for advancing immunoglobulin manufacturing technologies and expanding access to next-generation IVIG products worldwide.

Biological: GC5107

GC5107 is a 10% intravenous immunoglobulin formulation developed to treat primary immunodeficiency and other immune-mediated conditions. It functions by restoring protective IgG levels, reducing infection frequency, and offering consistent immunomodulatory effects across diverse clinical settings. GC Biopharma, the company behind GC5107, has extensive expertise in plasma-derived biologics and continuously invests in clinical development to strengthen its immunoglobulin portfolio and enhance therapeutic quality, safety, and global regulatory compliance.

Key Questions Answered in the Intravenous Immunoglobulin Pipeline Insight Report

• Which companies/institutions are leading the intravenous immunoglobulin development?
• Which company is leading the intravenous immunoglobulin pipeline development activities?
• What is the current intravenous immunoglobulin commercial assessment?
• What are the opportunities and challenges present in the intravenous immunoglobulin pipeline landscape?
• What is the efficacy and safety profile of intravenous immunoglobulin pipeline drugs?
• Which company is conducting major trials for intravenous immunoglobulin drugs?
• Which companies/institutions are involved in intravenous immunoglobulin collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in intravenous immunoglobulin?

Reasons To Buy This Report

The Intravenous Immunoglobulin Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for intravenous immunoglobulin. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into intravenous immunoglobulin collaborations, regulatory environments, and potential growth opportunities.